1	Effectiveness and clinical relevance of kinesio taping in musculoskeletal disorders: A
2	protocol for an overview of systematic reviews and evidence mapping
3	
4	Authors: Qingcong Mo <sup>a,#</sup> , Siqi Xu <sup>b,#</sup> , Fangfei Hu <sup>a</sup> , Xiaoyan Zheng <sup>b,*</sup>
5	<sup>#</sup> Qingcong Mo and Siqi Xu contributed equally to this work
6	
7	Affiliations:
8	<sup>a</sup> School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
9	<sup>b</sup> School of Rehabilitation Sciences, Southern Medical University, Guangzhou, China.
10	
11	*Corresponding authors:
12	Full name: Xiaoyan Zheng
13	Mailing address: School of Rehabilitation Sciences, Southern Medical University, 1023-1063
14	Shatai South Road, Guangzhou, China
15	E-mail address: zxy18825147762@smu.edu.cn
16	Phone: (+86) 18825147762
17	

#### 18 ABSTRACT

#### 19 Introduction

Kinesio taping (KT) has been extensively applied in the management of musculoskeletal disorders. Although plentiful systematic reviews (SRs) have evaluated its efficacy, there are no convincing conclusions due to disperse and inconclusive results, and its clinical relevance remains unclear. Hence, there is a need to summarise all the SRs for the comprehensive and consistent evidence. This overview aims to appraise the overall effectiveness of KT in musculoskeletal disorders, and provide evidence maps to visualise the findings.

#### 26 Method and analysis

Electronic databases (Cochrane Database of Systematic Reviews, MEDLINE, Embase, 27 Epistemonikos, PEDro, Scopus, ISI Web of Science) and reference lists will be searched from 28 inception to September 2024 for the SRs of randomised controlled trials (RCTs). The SRs 29 involving comparisons of the effectiveness between single or adjunctive KT and other 30 interventions for patients with musculoskeletal disorders will be included. The primary and 31 additional outcome to be considered will be the core outcome set, and the patient-reported 32 outcome measure and patient-important outcome, respectively. Two reviewers will 33 independently screen and select studies, extract the data, and evaluate the reporting and 34 methodological quality of eligible SRs as well as the risk of bias of included RCTs. For the SRs 35 without meta-analysis, we will collate the number of RCTs that showed any differences in 36 outcomes. For the SRs with meta-analysis, we will provide the original summary of evidence 37 (e.g., pooled effects and heterogeneity) for outcomes with an evaluation of missing results and 38 clinical relevance. The certainty of each outcome will be measured, and user-friendly maps of 39

40 findings will be presented graphically.

## 41 Ethics and dissemination

- 42 Formal ethical approval for this study is not required, since the data will be only collected from
- 43 published literature in public databases. The results will be disseminated in the peer-reviewed
- 44 academic journal, and relevant datasets will be preserved in the online repository.

# 45 **PROSPERO registration number**

#### 46 CRD42024517528

## 47 Strengths and limitations of this study

- This study will be carried out and reported following the Cochrane Collaboration
   Handbook for Overviews of Reviews and the Preferred Reporting items for Overviews of
   Reviews statement.
- This study will only include systematic reviews with and without meta-analysis of
   randomised controlled trials.
- This study will evaluate the reporting and methodological quality of systematic reviews,
   examine the risk of bias and degree of overlap of randomised controlled trials, and manage
   discordant results by selecting the most representative research.
- This study will perform the assessment of missing results and certainty for the evidence,
   interpret the clinical relevance between effects and outcomes, and provide evidence maps
   of comprehensive and systematic findings.
- This study may not be up-to-date as newly published randomised controlled trials will not
   be included, and ultimate conclusions will probably be limited by clinical heterogeneity
   due to variations in dose or application method of kinesio taping.

## 62 INTRODUCTION

Musculoskeletal disorders are a major and serious healthcare issue.[1] It consist of a group of 63 more than 150 different and irreversible diseases/conditions that affect the locomotor system 64 65 (including muscles, bones, joints and adjacent connective tissues).[2,3] Among them, the most prevalent conditions are low back pain, fractures, osteoarthritis, other injuries, neck pain, 66 amputation, and rheumatoid arthritis.[4,5] Globally, musculoskeletal disorders are common 67 among adolescents to the elderly, and the highest burden is expected to be concentrated in 68 people aged 50-54 years.[6,7] Over the past few decades, with the growth and 69 aging of population, musculoskeletal disorders have become increasingly serious.[4,5] 70

71 Estimates of the prevalence of musculoskeletal disorders suggested substantial increases in global cases and years of life lived with disability, affecting approximately 1.71 billion 72 individuals.[4,5] Patients with musculoskeletal disorders may suffer from various health-related 73 74 negative outcomes, involving problems in pain intensity, functional status, psychological state, quality of life, and more. [5,8,9] The consequences of these problems may lead to work-related 75 disability while reducing productivity and increasing direct and indirect economic 76 costs.[3,8,10,11] In addition, the risk of developing other noncommunicable diseases, 77 especially cardiovascular diseases, is higher in people with musculoskeletal disorders than in 78 those without them.[12] As a typical feature of musculoskeletal disorders, co-occurring 79 80 persistent pain in different body regions beyond the primary pain may have implications for patients' prognosis, treatment method, and outcome.[13,14] Hence, research on musculoskeletal 81 disorders requires more attention, although they mainly lead to disability rather than 82 death.[15,16] 83

84	In an attempt to meet the massive demand of rehabilitation services,[4,5] active
85	management for musculoskeletal disorders is needed.[16-18] Currently, non-invasive
86	treatments have a significant impact on the treatment of various musculoskeletal disorders.[15]
87	Among them, kinesio taping (KT), a form of taping technique, has been extensively utilized
88	across countries/regions for many years to support sports science and rehabilitation.[19] The
89	application of KT in musculoskeletal disorders is widespread.[20]

90

# 91 **Description of the intervention**

KT is an elastic therapeutic taping tool consisting mainly of cotton, originally created and 92 introduced by Dr. Kenso Kase in the 1970s.[21] It is lightweight, waterproof, breathable and 93 94 available in a wide range of colours, types, lengths, widths, textures and techniques.[21] Following assessment and instruction from healthcare professionals, KT can be directly fixed 95 to the target tissue with different combinations of cuts (e.g., Y, I, X tape), tensions (e.g., 96 percentage of stretch), and directions (e.g., muscle insertion to origin).[21] Wearing of KT may 97 maintain the effect for 3 to 5 days, ideally following the 24 hours application rule based on the 98 99 skin condition.[22]

Over the past decade, the popularity of KT is increasing worldwide given the promising benefits suggested by plentiful clinical studies.[19,22] KT assists users with musculoskeletal disorders in relieving pain intensity,[23] modulating extremity function,[23] and improving proprioception,[24] stability,[25] range of motion,[26] and quality of life.[27] These therapeutic effects are probably supported by the mechanisms of KT that it increases the subcutaneous space, stimulates skin sensory receptors, and provides support for mechanical behaviour and

106 biomechanics of the skin.[21,28-30] Applying different tensions of it on the skin may reduce partial pressure, accelerate blood and lymphatic circulation, and increase muscle temperature, 107 thus promoting regional microcirculation.[21,31,32] People with a psychologically anticipated 108 109 response to the effect of KT are likely to induce greater placebo effects, thus contributing to enhanced muscle function.[33-35] Although there is some evidence to support the theory of KT, 110 its precise working mechanism remains unclear and many studies showed conflicting 111 therapeutic results.[36] Consequently, the inconclusive findings of KT have resulted in a 112 longstanding debate regarding the effectiveness and clinical relevance. 113

114

## 115 Significance of conducting the review

Due to substantial controversy over the results of KT reported in the primary studies, researchers have carried out plentiful systematic reviews (SRs) with and without meta-analysis to evaluate the clinical effectiveness of KT.[37-40] However, the inconclusive evidence of musculoskeletal disorders was presented in the SRs as well, involving elbow,[41,42] shoulder,[43-45] back,[46-48] knee,[49-51] and spine.[52]

Meanwhile, the majority of SRs may not examine the clinical relevance of KT. The minimal clinically important difference (MCID) is considered to be the smallest change that appears to have a benefit implication for patient's treatment outcome.[53,54] The application of MCID assists in establishing numerical thresholds for clinical research that only identified statistically significant impacts of intervention with little or unknown clinical relevance for patients.[55-57] Nevertheless, Embry and Piccirillo retrieved the journal and found that large percentage of randomised controlled trials (RCTs) (69%) did not define the MCID or mention 128 it.[58] The lack of additional confirmation regarding the clinical relevance of KT presumably129 added difficulties to clinical interpretation of its effects.

As the number of SRs increased to date, the existing evidence of KT probably created gaps between research and practice, as well as variations in clinical opinions among healthcare providers.[59,60] Hence, there is a need to summarise and assess the overall effectiveness of KT in musculoskeletal disorders from all the SRs.

Overview of SRs, a method of reviewing multiple SRs, is capable of collating broad 134 information, synthesizing diverse findings, and presenting a well-organized and detailed 135 summary of evidence.[61,62] This evidence-based method is frequently applied to develop a 136 137 unified perspective when there are conflicting conclusions on a specific topic at the level of the SRs due to different selection methods, potential sources of heterogeneity and risk of bias, and 138 variable reporting and methodological quality.[61,62] In addition, evidence mapping is a 139 effective and evolving methodological tool for integrating and presenting evidence through 140 user-friendly visual graphics.[63,64] Cupler and colleagues have provided an evidence map of 141 four types of taping (KT, Rigid taping, McConnell taping and Mulligan taping) for 142 musculoskeletal conditions.[65] However, the limitation of the study is that the evidence maps 143 were based on the included RCTs and did not clarify the relationship between the outcomes and 144 the contradictory findings of the SRs. Application of evidence mapping for overview of SRs 145 146 plays a complementary role in conveniently identifying research gaps and rapidly disseminating knowledge.[63,64,66,67] 147

148 To date, no studies have evaluated the existing evidence on the effectiveness and clinical 149 relevance of KT in musculoskeletal disorders from the SRs. To fill the gap of knowledge, we

150	will conduct an overview of SRs and evidence mapping to inform evidence-based clinical
151	practice and support healthcare decision-making. The relevant findings obtained by this study
152	will be expected to benefit researchers, physiotherapists, stakeholders, and particularly multiple
153	patients at various stages of musculoskeletal rehabilitation.
154	
155	Objective and research question
156	This study aims to appraise the overall effectiveness of KT in musculoskeletal disorders, and
157	provide evidence maps to visualise the findings. This study will examine the following research
158	questions: (1) Is KT effective in patients diagnosed with musculoskeletal disorders? (2) What
159	types of outcomes does KT demonstrate positive, no, or negative effects on?
160	
161	
	METHODS AND ANALYSIS
162	METHODS AND ANALYSIS Protocol and registration
162 163	METHODS AND ANALYSIS Protocol and registration This study is designed as an overview of SRs and evidence mapping. We have prospectively
162 163 164	METHODS AND ANALYSIS Protocol and registration This study is designed as an overview of SRs and evidence mapping. We have prospectively registered this protocol within the International Prospective Register of Systematic Reviews
162 163 164 165	METHODS AND ANALYSIS Protocol and registration This study is designed as an overview of SRs and evidence mapping. We have prospectively registered this protocol within the International Prospective Register of Systematic Reviews (PROSPERO, Registration number: CRD42024517528). The protocol has been presented in
162 163 164 165 166	METHODS AND ANALYSIS Protocol and registration This study is designed as an overview of SRs and evidence mapping. We have prospectively registered this protocol within the International Prospective Register of Systematic Reviews (PROSPERO, Registration number: CRD42024517528). The protocol has been presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
<ol> <li>162</li> <li>163</li> <li>164</li> <li>165</li> <li>166</li> <li>167</li> </ol>	METHODS AND ANALYSIS Protocol and registration This study is designed as an overview of SRs and evidence mapping. We have prospectively registered this protocol within the International Prospective Register of Systematic Reviews (PROSPERO, Registration number: CRD42024517528). The protocol has been presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statement (Supplementary File 1).[68] We will conduct the overview
<ol> <li>162</li> <li>163</li> <li>164</li> <li>165</li> <li>166</li> <li>167</li> <li>168</li> </ol>	METHODS AND ANALYSIS Protocol and registration This study is designed as an overview of SRs and evidence mapping. We have prospectively registered this protocol within the International Prospective Register of Systematic Reviews (PROSPERO, Registration number: CRD42024517528). The protocol has been presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statement (Supplementary File 1).[68] We will conduct the overview following the methodology of Cochrane Collaboration Handbook for Overviews of
<ol> <li>162</li> <li>163</li> <li>164</li> <li>165</li> <li>166</li> <li>167</li> <li>168</li> <li>169</li> </ol>	METHODS AND ANALYSIS Protocol and registration This study is designed as an overview of SRs and evidence mapping. We have prospectively registered this protocol within the International Prospective Register of Systematic Reviews (PROSPERO, Registration number: CRD42024517528). The protocol has been presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statement (Supplementary File 1).[68] We will conduct the overview following the methodology of Cochrane Collaboration Handbook for Overviews of Reviews.[69]

170

# 171 Patient and public involvement

172 No patients or the public involved in this overview of SRs and evidence mapping.

173

# 174 Eligibility criteria

175 Types of studies

Standard-compliant SRs with and without meta-analysis of RCTs will be considered for 176 inclusion. The definition of systematic review and meta-analysis will be adhered to the 177 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 178 statement, [70] as follows: systematic review means to use explicit, systematic methods to 179 collate and synthesise findings of studies that address a articulated question; meta-analysis is a 180 181 statistical method for synthesising results when research effect estimates and their variances are available. If the SRs were published in other languages than English, or only searched one 182 database, or no details of primary RCTs were provided, they will be excluded. Protocols of 183 overview and SRs, scoping review and network meta-analysis will be excluded as well. 184

185

186 Types of participants

Guided by the International Classification of Diseases 11th revision (ICD-11),[71] we will include participants who have a diagnosis of musculoskeletal disorders. Eligible individuals will be included, regardless of their age, gender, and region. Additionally, we will exclude animals from participation.

191

192 Types of interventions

193 The SRs that evaluated the effectiveness of KT in musculoskeletal disorders will be considered

194	for inclusion. KT must be used as a core treatment method in the experimental group, either as
195	monotherapy or combination therapy. The way of applying KT on the body must be related to
196	the musculoskeletal system. It will not be limited by tension, direction, and regimen.
197	
198	Types of comparators
199	No strict intervention limitations on the type of control group will be set, such as no treatment,
200	standard of care, placebo control, medication therapy, rehabilitation, and other interventions
201	(e.g., traditional Chinese medicine therapy, surgical treatment). KT as a treatment method will
202	be excluded in this group.
203	
204	Types of outcome measures
205	With the ability to lower the risk of heterogeneity, inconsistency, and outcome-reporting bias
206	between trials, the core outcome set will be the primary outcome.[72] First, we will search
207	specific musculoskeletal disorders related to KT usage in eligible SRs on the MEDLINE or the
208	website (https://comet-initiative.org/). Then, we will select the most up-to-date (i.e., date
209	approaching 2022-2024), credible (e.g., registered research, multi-round survey, more
210	stakeholders included), and standard (e.g., reported more complete items in the checklist of
211	Core Outcome Set-STAndards for Development)[73] core outcome set to consider any
212	promising outcomes that must be relevant to patients.
213	If partial musculoskeletal disorders are not assessed by the core outcome set, we plan to
214	consider patient-reported outcome measures [74] and patient-important outcomes.[75] They are

able to reflect patient perspectives on their symptoms, functional status, quality of life, and

- 216 more. The following additional outcomes will be considered:
- 1. Pain intensity, which measured by standard or specific scales (e.g., Numerical Rating Scale
- 218 (NRS), Visual Analogue Scale (VAS)).
- 219 2. Upper and lower limb function and/or disability status, which measured by standard or
- 220 specific scales (e.g., Range of Motion (ROM), Disabilities of the Arm, Shoulder and Hand
- 221 (DASH), Victorian Institute of Sport Assessment-Patella Questionnaire (VISA-P), Roland-
- 222 Morris Disability Questionnaire (RMDQ)).
- 223 3. Quality of life, which measured by standard or specific scales (e.g., Short-Form 36 Health
- 224 Survey Questionnaire (SF-36), EORTC Core Quality of Life questionnaire (EORTC QLQ-C30),
- 225 WHO Quality of Life Brief Questionnaire (WHOQOL-BREF)).
- 4. Disease-specific symptom, which measured by standard or specific scales (e.g., Grip Strength(GS) for lateral epicondylitis).
- 228

### 229 Search strategy and selection

According to the Preferred Reporting Items for Systematic reviews and Meta-Analyses 230 literature search extension (PRISMA-S) guideline, [76] our search will be conducted in the 231 following electronic databases (Cochrane Database of Systematic Reviews, MEDLINE, 232 Embase, Epistemonikos, PEDro, Scopus, ISI Web of Science) from inception to September 233 234 2024. We will also perform a search to identify any registered yet unpublished SRs and grey literature in the PROSPERO and OpenGrey, respectively. In addition, we will hand-search the 235 reference lists of included SRs for any relevant cited SRs in Google Scholar. The search strategy 236 is developed involving the integration of MeSH terms, keywords and free text terms related to 237

KT: (kinesio taping OR kinesio tape OR kinesiotaping OR kinesiotap OR physiotape OR tape
OR taping) AND (systematic review OR meta-analysis).

Two independent literature reviewers will screen titles and abstracts of the SRs output 240 through the EndNote V.21 software to identify eligible articles. Then, the same reviewers will 241 download the promising SRs and assessed them by full-text reading for final inclusion. 242 Afterwards, applying Gwet's AC1 statistics and related 95% confidence interval (CI),[77] one 243 reviewer will evaluate the agreement on study selection between two reviewers using R 244 language V.4.3.2. Considering that application of the classification from Landis and Koch to 245 Gwet's AC1 is inappropriate, [78] the inter-rater reliability will be cautiously explained. The 246 247 Fisher's exact test will be performed to determine its statistical significance (P value). Any disagreement will be discussed or consulted the third reviewer for a consensus. 248

249

#### 250 Data extraction

We will extract and cross-check data from the SRs in standardised tables based on predefined 251 criteria, using an electronic form of Microsoft Excel 2019. All data must be related to KT only. 252 253 Data concerning the basic information (first author's name, year of publication, country/region of the first author's affiliation, and number of the included primary RCTs), participants 254 characteristic (number of participants and disease or condition), search strategy (number and 255 names of databases searched and date range of search), type of comparison, outcome 256 measurement, evidence assessment tool (risk of bias and certainty of evidence) and study 257 conclusion (e.g., positive effect, no effect, negative effect) will be extracted. If we identified 258 discrepant data of included same studies in different SRs, we plan to contact the corresponding 259

authors or to retrieve and follow the raw data of primary RCTs.

If the SRs with meta-analysis analysed outcomes with more than one study, two reviewers will extract the analytical methods (fixed or random effects model), heterogeneity (Cochran's Q test P value and I-square statistic), pooled effects with 95% CI (mean difference (MD) or standardized mean difference (SMD) for continuous outcome; relative risk (RR) or odds ratio (OR) for binary outcome), direction (differences in favour of KT or control intervention), statistical significance (P value) and publication bias (at least 10 studies). If the follow-up data is available, we will extract them as well.

To provide a complete summary of KT, we will use the Risk of Bias due to Missing 268 269 Evidence (ROB-ME) tool to assess the meta-analysis results.[79] Briefly, three steps will be 270 conducted following the tool: select meta-analyses related to outcome (step 1), determine which eligible studies have missing results (step 2), and consider potential for missing studies (step 3). 271 Response options for the signal questions are categorised as 'yes', 'probably yes', 'probably 272 no', 'no', 'no information' or 'not applicable'. Then, the results will be judged and interpreted 273 as 'low risk of bias', 'some concerns' or 'high risk of bias'. Discrepancies considered potentially 274 relevant by one reviewer will be discussed and, if needed, will be ultimately resolved by the 275 third reviewer. 276

277

#### 278 Managing the overlap between primary RCTs

As the number of SRs and updated SRs for KT increased to date, the identical or highly similar questions related to musculoskeletal disorders were probably answered.[80] To avoid double counting data from overlapped SRs, we will extract the information on characteristics of

primary RCTs separately (first author's name, year of publication, number of participants, type
of comparison, pre- and post-intervention outcome measurement data with or without followup). After removing duplicated articles, we will combine the results into a table.

Based on the specific clinical question, a matrix of included primary RCTs in the SRs will be created and visualised to evaluate the amount of overlapping using the Graphical Representation of Overlap for OVErviews (GROOVE) tool.[81] When collating each outcome in the matrix, we will calculate the corrected covered area (CCA) regardless of any structural missing data. The CCA refers to a measurement for the degree of overlap and it will be interpreted as 'slight overlap' (0%–5%), 'moderate overlap' (6%–10%), 'high overlap' (11%– 15%) or 'very high overlap' (>15%).[82]

292

#### 293 Assessment of the reporting quality

Transparent and complete reporting of SRs supports to examine the feasibility of the methods 294 and the reliability of the findings, thus bolstering evidence-based decision-making.[70,83] Two 295 reviewers will separately evaluate the reporting quality of SRs with and without meta-analysis 296 297 in accordance with the Synthesis without meta-analysis (SWiM) reporting guideline [83] and the PRISMA 2020 statement.[70] The SwiM guideline consists of 9 items and contains critical 298 features of synthesis in the SRs without meta-analysis (e.g., the method of study category, data 299 300 presentation, finding summary). The PRISMA checklist covers 27 items and is designed for SRs with meta-analysis that require detailed reporting in different sections (e.g., abstract, 301 methods, results). Each item of the above checklist will be recorded and graded as 'completely 302 reported', 'partially reported' or 'not reported' depending on whether the domains were clearly 303

documented. Then, we will calculate the compliance rate of the reporting in each of SRs to overview the overall reporting quality. Any differences of opinion will be resolved through discussion or determined by the third reviewer.

307

## 308 Assessment of the methodological quality and the risk of bias

The quality assessment of eligible SRs includes both the methodological quality and the risk of 309 bias [84]. Two reviewers will independently assess them by the A Measurement Tool to Assess 310 Systematic Reviews 2 (AMSTAR 2) [85] and Risk of Bias in Systematic reviews (ROBIS),[86] 311 respectively. The AMSTAR 2 is a valid, reliable and user-friendly appraisal tool and most of 312 313 the questions are binary.[87] After answering 16 original items (recommended critical domains 314 are 2, 4, 7, 9, 11, 13, and 15), the overall methodological confidence of SRs will be judged as follows: 'high' (no or one non-critical weakness), 'moderate' (more than one non-critical 315 weakness), 'low' (one critical flaw with or without non-critical weaknesses) or 'critically 316 low' (more than one critical flaw with or without non-critical weaknesses). The ROBIS 317 has rigorous methodology and is intended for assessing the level of bias within SRs through 318 three phases: assess the relevance of SRs to outcome for KT (phase 1), identify concerns with 319 the review process including study eligibility criteria, identification and selection of studies, 320 data collection and study appraisal, synthesis and findings (phase 2), judge the risk of bias based 321 322 on the concerns of each domain bias (phase 3).[86] The overall risk of bias will be rated as 'low', 'unclear' or 'high' according to the answers to signalling questions. 323

In addition, we plan to re-evaluate the quality of each primary RCTs using the Cochrane Risk of Bias assessment tool 2.0 (ROB 2.0),[88] if the SRs appraised the risk of bias by means

of other tool (e.g., Cochrane risk of bias tool, Jadad scale, PEDro scale). The ROB 2.0 consists of five bias domain originating from the randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome and selection of the reported result. Each domain will be required to rank the levels of evidence bias through a series of signalling questions to determine the judgement of overall risk of bias as 'low risk of bias', 'some concerns' or 'high risk of bias'.[88] Any differences will be settled through discussion or with the assistance of the third reviewer.

333

#### 334 Strategies for data analysis

Within the SRs without meta-analysis, we will collate and summarise the number of RCTs that 335 demonstrated any differences in the outcomes (i.e., statistically significant positive effect 336 [direction of effect in favour of KT], statistically significant negative effect [direction of effect 337 in favour of control intervention] and non-statistically significant effect). Statistical significance 338 will be defined as a P value less than 0.05.[89] If the SRs incorporated comparisons that did not 339 meet the eligible inclusion criteria, the corresponding RCTs will not be applicable for 340 calculation. Using the vote counting method, we plan to present these RCTs as a percentage of 341 all primary studies in the SRs along with 95% CI (Wilson interval).[90] 342

Regarding the SRs with meta-analysis, we will present the original summary of evidence (e.g., pooled effects, heterogeneity and direction) without carrying new meta-analyses for outcomes. However, when the same conceptual outcome that included interventions beyond KT (e.g., Rigid taping, McConnell taping, Mulligan taping) or was reported by different measurements (e.g., outcome of interest that should be calculated in MD but was calculated in

SMD), we plan to back-translate the primary data in the SRs to re-estimate the overall effects. 348 For re-analysing the outcome data that incorporated other distinct types of KT, we will exclude 349 these RCTs by examining the characteristics of primary studies. Then, the associated findings 350 351 (i.e., pooled effects, heterogeneity and direction) will be extracted, and the publication bias (at least 10 RCTs) will be evaluated by the Egger's regression test. For the conversion of 352 appropriate outcome measurements, we will present the binary outcomes as RR since the usage 353 of OR in RCTs may exaggerate the effect size, leading to the misinterpretation in decision-354 making.[91,92] And the continuous outcomes will be presented as MD (same conceptual 355 outcomes are measured on same scales) or SMD (same conceptual outcomes are measured on 356 357 different scales).[93] In the above procedures, to maximise the retention of the authors' data processing methods, the re-estimation will be performed under the same settings corresponding 358 to the SRs using the Review Manager V.5.4 software. 359

360

### 361 Strategies for managing concordant or discordant results

To provide the concordant evidence, we will organise the final results of KT (i.e., the proportion of RCTs that showed any effect and the overall pooled effects) from the SRs with and without meta-analysis into three categories (positive effect, no effect, and negative effect).[69] Table 1 provides detailed criteria for classification. A threshold of 80% SRs in the same classification will be set to determine the concordance of results [94] and the robustness of review findings will be discussed.[95]

368

Type of systematic review	Category of effect	Description
Systematic review without	Positive effect	The proportion of RCTs that showed
meta-analysis		statistically significant effect in favour of KT
		is the highest
	No effect	The proportion of RCTs that showed non-
		statistically significant effect is the highest
	Negative effect	The proportion of RCTs that showed
		statistically significant effect in favour of
		control intervention is the highest
Systematic review with	Positive effect	Continuous outcome: the statistically
meta-analysis		significant pooled effect size and associated
		95% CI is higher than 0 points (direction of
		effect in favour of KT)
		Dichotomous outcome: the statistically
		significant pooled effect size and associated
		95% CI is higher than 1 points (direction of
		effect in favour of KT)
	No effect	Continuous outcome: the associated 95% CI of
		pooled effect size crosses 0 points
		Dichotomous outcome: the associated 95% CI
		of pooled effect size crosses 1 points
	Negative effect	Continuous outcome: the statistically
		significant pooled effect size and associated
		95% CI is lower than 0 points (direction of
		effect in favour of control intervention)
		Dichotomous outcome: the statistically
		significant pooled effect size and associated
		95% CI is lower than 1 points (direction of
		effect in favour of control intervention)

369 **Table 1** Effects classification criteria. CI, confidence interval; RCTs, randomised controlled

370 trials; KT, kinesio taping.

371

When there are discordant results, methods of treatment involves examining and recording discordance, using adjunct decision rules or tools, and selecting the most representative study among the SRs.[96] In this management, we will consider varied standards for choosing the best SR, as the new meta-analyses will not be conducted and the utilization of Jadad algorithm

376	will be difficult to follow (i.e., limitations in operationalization and interpretation).[97] First,
377	we will examine the resemblance of clinical question (e.g., moderate to very high overlap
378	presented in CCA, similar scale used to combine effect size) across the SRs. Afterwards, the
379	four-domain strategies (comprehensiveness, timeliness, riskiness, and reporting) will be applied
380	to select the best SR that reported relatively trustworthy findings, as below:
381	1. Comprehensiveness: the SRs included the highest number of RCTs and participants.
382	2. Timeliness: the SRs conducted the most recent search date (i.e., date approaching 2022-2024)
383	in the largest number of databases (e.g., MEDLINE, Embase, CINAHL).
384	3. Riskiness: the SRs that were evaluated as the highest methodological quality and the lowest
385	risk of bias according to the AMSTAR 2 and ROBIS tool.
386	4. Reporting: the SRs reported the most complete items (number of items completely reported
387	and partially reported) in the checklist of the SwiM guideline and the PRISMA 2020 statement.
388	

## 389 Assessment of the certainty of evidence

Certainty of evidence supports the clinical and health decision-making process and its assessment is an essential part of overview of SRs according to the Cochrane guidelines.[98,99] For the SRs without meta-analysis, we will assess the overall quality of evidence following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework.[100] Details of the application of the GRADE framework in the SRs without metaanalysis are in Supplementary File 2.

396 If the SRs with meta-analysis used the GRADE methodology to determine the quality of 397 evidence, we will extract and present the following information associated with outcomes: five

398	domains of downgrade (risk of bias, inconsistency, indirectness, imprecision and reporting bias).
399	three domains of upgrade (large effects, dose response and opposing plausible residual bias and
400	confounding) and the corresponding certainty (high quality, moderate quality, low quality and
401	very low quality).[101] In contrast, if these SRs did not report the certainty of evidence, we will
402	evaluate the overall quality of summary of evidence by the GRADE methodology.

403

# 404 Assessment and interpretation of clinical relevance

We propose comparing the continuous pooled effects with 95% CI from each meta-analysis to 405 the MCID. With the increasing publication of MCID measurements involving different 406 407 outcomes in musculoskeletal disorders, [102-105] there may be overlap. Hence, we will search 408 and select the MCID that most closely resemble the outcomes and participants in electronic databases corresponding to our search strategy (e.g., MEDLINE, Embase, ISI Web of Science). 409 410 Priority consideration will be given to the MCID determined through anchor-based methods. The MCID described as percentage change from baseline for outcomes will not be considered 411 since this method may not be suitable for statistical analysis.[106] If the included MCID is 412 413 appropriate, the pooled effects reported in MD will be directly compared to it. The pooled effects reported in SMD will not be compared to the MCID as various lumped scales may lead 414 to substantial uncertainty. Nevertheless, when the pooled effects reported in SMD is greater 415 416 than 0.5 (medium effect size), we will consider the difference between KT and other interventions as the MCID.[55,93] If the appropriate MCID is not available, we will select and 417 use the standard deviation for distribution-based calculation.[55,56] Details of the calculation 418 of clinical relevance are in Supplementary File 3. 419

420	Subsequently, we will adopt the systematic method provided from Man-Son Hing et al. to
421	determine and interpret the clinical relevance of results (Figure 1).[107] The approach focuses
422	on four levels of clinical importance between the MCID and the pooled effects with 95% CI, as
423	below:
424	1. Definite: the lower limit of the 95% CI is greater than the MCID.
425	2. Probable: the lower limit of the 95% CI is smaller than the MCID, but the pooled effect size
426	is greater than the MCID.
427	3. Possible: the pooled effect size is smaller than the MCID, but the upper limit of the 95% CI
428	is greater than the MCID.
429	4. Definitely not: the upper limit of the 95% CI is smaller than the MCID.
430	
431	Evidence mapping of findings
432	To provide credible evidence maps related to KT, we will summarise the evidence from the SRs

and create user-friendly matrices of the relationship between effectiveness (positive effect, no 433 effect, and negative effect) and outcomes. Then, we will grade the strength of evidence into five 434 levels (convincing, highly suggestive, suggestive, weak, and non-significant evidence).[108-435 110] For the SRs without meta-analysis, we will evaluate the strength of evidence of positive 436 or negative effects using the binomial test. This test (null hypothesis is equal to 0.5) will be 437 438 applied to detect whether KT has a true effect.[90] For the SRs with meta-analysis, the strength of evidence will be assessed through strict criteria (e.g., number of participants and statistical 439 significance). We will calculate the 95% prediction interval from the primary study specific 440 data that corresponds to the SRs for outcomes. We plan to examine the excess of statistically 441

442 significant bias by detecting whether the number of observed nominally significant studies

- 443 differs from the expected number of research with significant results.[111] Details of the
- 444 classification criteria for strength of evidence are in Table 2.
- 445

Type of systematic review	Strength of evidence	Description
Systematic reviews with	Class I: convincing	Number of included participants>1000;
meta-analysis	evidence	statistical significance at P<10 <sup>-6</sup> ; no
Systematic reviews with meta-analysis		large heterogeneity (I-square<50%);
		95% prediction interval not including
		null value; no small-study effects; no
		excess significance bias
	Class II: highly	Number of included participants>1000;
	suggestive evidence	statistical significance at P<10 <sup>-6</sup> ; largest
		study significant
	Class III: suggestive	Number of included participants>1000;
	evidence	statistical significance at P<10 <sup>-3</sup>
	Class IV: weak evidence	Statistical significance at P<0.05
	Non-significant evidence	Statistical significance at P>0.05
Systematic reviews without	Class I: convincing	Probability of observing the evidence if
meta-analysis	evidence	positive or negative effects are not true
		at P<0.05
	Class IV: weak evidence	Probability of observing the evidence if
		positive or negative effects are not true
		at P>0.05
	Non-significant evidence	Evidence of no effect observed

- 446 **Table 2** Classification criteria of strength of evidence.
- 447

## 448 Strategies for evidence synthesis

We will report the overview following the Preferred Reporting items for Overviews of Reviews (PRIOR) statement.[112] The selection of the SRs will be reported using the PRISMA flow chart in accordance with the PRISMA-S guideline, and the associated inter-rater reliability (Gwet's AC1 statistics) will be presented in narrative form. A list of included and excluded SRs

453 will be provided with descriptive explanation of reasons.

454	The characteristics of the included SRs regarding the relevant details of basic information,
455	participant characteristic, search strategy, type of comparison, outcome measurement, evidence
456	assessment tool and study conclusion will be summarised and reported in tabular form. The
457	matrix of evidence table at the outcome level will be visually presented in the heat map graphics
458	that informed the degree of overlap between primary RCTs in the SRs.

We will report the results concerning the quality of the RCTs (risk of bias assessed by the ROB 2.0 tool) and the quality of the SRs (reporting assessed by the SWiM guideline and the PRISMA 2020 statement, methodology assessed by the AMSTAR 2, risk of bias assessed by the ROBIS tool) in tables. The final summary of evidence (the proportion of RCTs that showed any effect and the overall pooled effects) will be tabulated, along with the discussion of sensitivity to concordant or discordant results.

The effectiveness (positive, unclear, negative effect) of KT for each outcome of interest in musculoskeletal disorders will be presented accompanied by the clinical relevance and certainty of evidence using tables and figures. The visual evidence maps of evidence (the relationship between effectiveness and outcomes) with the corresponding strengths will be plotted, subgrouped by different body regions (lower extremity, upper extremity, spinal conditions, and not otherwise classified).[65]

471

### 472 ETHICS AND DISSEMINATION

This overview of SRs and evidence mapping does not require ethical approval, as the data will
be only collected from published literature in public databases. This results will be published

- in the peer-reviewed academic journal, and relevant datasets will be preserved in the online
- 476 repository.
- 477

## 478 AUTHORS' CONTRIBUTIONS

479	QM and SX, as co- first authors, made equal contributions to the study. QM, SX, FH and XZ
480	contributed to the conception and design of the study. SX and FH designed the eligibility criteria
481	and search strategies. QM, SX and FH developed the study quality evaluation, data extraction
482	and analysis plan, and evidence presenting method. XZ is the study guarantor. All authors
483	drafted the protocol and approved the final version for publication.

484

# 485 FUNDING STATEMENT

486 This work was supported by the National Natural Science Foundation of China (No. 82205245),

the Natural Science Foundation of Guangdong, China (No. 2023A1515011143), the Science
and Technology Program of Guangzhou, China (No. 2023A04J0421), the Teaching quality and
teaching reform project of Southern Medical University in 2022 ( [2022] 22), the National
College Student Innovation and Entrepreneurship Training Program (No. 202212121048 and

491 202312121264).

492

# 493 ACKNOWLEDGEMENTS

494 Not applicable.

495

#### 496 **COMPETING INTERESTS STATEMENT**

All authors have completed the ICMJE uniform disclosure form (www.icmje.org/disclosure-ofinterest/) and declare: no support from any organization for the submitted work; no financial
relationships with any organizations that might have an interest in the submitted work in the

500 previous three years; no other relationships or activities that could appear to have influe
---

501 the submitted work.

502

# 503 DATA SHARING

504 No additional data are available.

505

# 506 **REFERENCES**

- 507 [1] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and
- 508 injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global
- 509 Burden of Disease Study 2019. *Lancet* 2020;396:1204-22. doi:10.1016/S0140-

#### 510 6736(20)30925-9

- 511 [2] Gómez-Galán M, Pérez-Alonso J, Callejón-Ferre ÁJ, et al. Musculoskeletal disorders:
- 512 OWAS review. *Ind Health* 2017;55:314-37. doi:10.2486/indhealth.2016-0191
- 513 [3] World Health Organization. Musculoskeletal health [online]. 2022.
- 514 https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions (accessed
  515 23 January 2024).
- 516 [4] Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation
- based on the Global Burden of Disease study 2019: a systematic analysis for the Global
- 518 Burden of Disease Study 2019. *Lancet* 2021;396:2006-17. doi:10.1016/S0140-
- 519 6736(20)32340-0
- 520 [5] Chen N, Fong DYT, Wong JYH. Secular Trends in Musculoskeletal Rehabilitation Needs
- 521 in 191 Countries and Territories From 1990 to 2019. *JAMA Netw Open* 2022;5:e2144198.

- 522 doi:10.1001/jamanetworkopen.2021.44198
- 523 [6] Guan SY, Zheng JX, Sam NB, et al. Global burden and risk factors of musculoskeletal
- disorders among adolescents and young adults in 204 countries and territories, 1990-
- 525 2019. Autoimmun Rev 2023;22:103361. doi:10.1016/j.autrev.2023.103361
- 526 [7] Liu S, Wang B, Fan S, et al. Global burden of musculoskeletal disorders and attributable
- 527 factors in 204 countries and territories: a secondary analysis of the Global Burden of
- 528 Disease 2019 study. *BMJ Open* 2022;12:e062183. doi:10.1136/bmjopen-2022-062183
- 529 [8] Briggs AM, Cross MJ, Hoy DG, et al. Musculoskeletal Health Conditions Represent a
- 530 Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World
- 531 Report on Ageing and Health. *Gerontologist* 2016;56 Suppl 2:S243-55.
- 532 doi:10.1093/geront/gnw002
- 533 [9] Chen N, Fong DYT, Wong JYH. Trends in Musculoskeletal Rehabilitation Needs in
- 534 China From 1990 to 2030: A Bayesian Age-Period-Cohort Modeling Study. *Front Public*
- 535 *Health* 2022;10:869239. doi:10.3389/fpubh.2022.869239
- 536 [10] Bevan S. Economic impact of musculoskeletal disorders (MSDs) on work in
- 537 Europe. Best Pract Res Clin Rheumatol 2015;29:356-73. doi:10.1016/j.berh.2015.08.002
- 538 [11] Dieleman JL, Cao J, Chapin A, et al. US Health Care Spending by Payer and Health
- 539 Condition, 1996-2016. *JAMA* 2020;323:863-84. doi:10.1001/jama.2020.0734
- 540 [12] Williams A, Kamper SJ, Wiggers JH, et al. Musculoskeletal conditions may increase the
- risk of chronic disease: a systematic review and meta-analysis of cohort studies. *BMC*
- 542 *Med* 2018;16:167. doi:10.1186/s12916-018-1151-2
- 543 [13] El-Tallawy SN, Nalamasu R, Salem GI, et al. Management of Musculoskeletal Pain: An

- 544 Update with Emphasis on Chronic Musculoskeletal Pain. *Pain Ther* 2021;10:181-209.
- 545 doi:10.1007/s40122-021-00235-2
- 546 [14] Øverås CK, Nilsen TIL, Søgaard K, et al. Temporal stability in the prevalence and pattern
- 547 of co-occurring musculoskeletal pain among people with persistent low back pain:
- 548 population-based data from the Norwegian HUNT Study, 1995 to 2019. *Pain*
- 549 2023;164:2812-21. doi:10.1097/j.pain.00000000002981
- 550 [15] Belluzzi E, Pozzuoli A, Ruggieri P. Musculoskeletal Diseases: From Molecular Basis to
- 551 Therapy. *Biomedicines* 2023;12:32. doi:10.3390/biomedicines12010032
- 552 [16] Safiri S, Kolahi AA, Cross M, et al. Prevalence, Deaths, and Disability-Adjusted Life
- 553 Years Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-
- 554 2017. Arthritis Rheumatol 2021;73:702-14. doi:10.1002/art.41571
- 555 [17] Woolf AD, Erwin J, March L. The need to address the burden of musculoskeletal
- 556 conditions. *Best Pract Res Clin Rheumatol* 2012;26:183-224.
- 557 doi:10.1016/j.berh.2012.03.005
- [18] Lewis R, Gómez Álvarez CB, Rayman M, et al. Strategies for optimising
- 559 musculoskeletal health in the 21<sup>st</sup> century. *BMC Musculoskelet Disord* 2019;20:164.
- 560 doi:10.1186/s12891-019-2510-7
- 561 [19] Qin Y, Li M, Han J, et al. Research hotspots and trends of Kinesio Taping from 2011 to
- 562 2020: a bibliometric analysis. *Environ Sci Pollut Res Int* 2023;30:2029-41.
- 563 doi:10.1007/s11356-022-22300-9
- [20] Tran L, Makram AM, Makram OM, et al. Efficacy of Kinesio Taping Compared to Other
- 565 Treatment Modalities in Musculoskeletal Disorders: A Systematic Review and Meta-

566	Analysis. Res Sports Med 2023;31:416-39. doi:10.1080/15438627.2021.1989432
567	[21] Kase K, Wallis J, Kase T. Clinical Therapeutic Applications of the Kinesio Taping
568	Method: 3rd Edition. Albuquerque, NM: Kinesio Taping Association 2013:1-41.
569	[22] Andrýsková A, Lee JH. The Guidelines for Application of Kinesiology Tape for
570	Prevention and Treatment of Sports Injuries. Healthcare 2020;8:144.
571	doi:10.3390/healthcare8020144
572	[23] Rahlf AL, Braumann KM, Zech A. Kinesio Taping Improves Perceptions of Pain and
573	Function of Patients With Knee Osteoarthritis: A Randomized, Controlled Trial. J Sport
574	Rehabil 2019;28:481-7. doi:10.1123/jsr.2017-0306
575	[24] Cho HY, Kim EH, Kim J, et al. Kinesio taping improves pain, range of motion, and
576	proprioception in older patients with knee osteoarthritis: a randomized controlled
577	trial. Am J Phys Med Rehabil 2015;94:192-200. doi:10.1097/PHM.000000000000148
578	[25] Safari S, Mohsenifar H, Amiri A. The immediate effect of synergistic muscles kinesio
579	taping on function and balance of volleyball players with functional ankle instability: A
580	randomized controlled trial. Foot 2023;57:102058. doi:10.1016/j.foot.2023.102058
581	[26] Ay S, Konak HE, Evcik D, et al. The effectiveness of Kinesio Taping on pain and
582	disability in cervical myofascial pain syndrome. Rev Bras Reumatol Engl Ed 2017;57:93-
583	9. doi:10.1016/j.rbre.2016.03.012
584	[27] Espí-López GV, Inglés M, Ferrando AC, et al. Effect of Kinesio taping on clinical
585	symptoms in people with fibromyalgia: A randomized clinical trial. J Back Musculoskelet
586	Rehabil 2019;32:561-7. doi:10.3233/BMR-171100
587	[28] Alqahtani AS, Parveen S. Kinesio Taping as a Therapeutic Tool for Masticatory

- 588 Myofascial Pain Syndrome-An Insight View. Int J Environ Res Public Health
- 589 2023;20:3872. doi:10.3390/ijerph20053872
- 590 [29] Cimino SR, Beaudette SM, Brown SHM. Kinesio taping influences the mechanical
- 591 behaviour of the skin of the low back: A possible pathway for functionally relevant
- 592 effects. *J Biomech* 2018;67:150-6. doi:10.1016/j.jbiomech.2017.12.005
- [30] He F, Wang X, Yu M, et al. Effects of Kinesio taping on skin deformation during knee
- flexion and extension: a preliminary study. *BMC Musculoskelet Disord* 2022;23:187.
- 595 doi:10.1186/s12891-022-05148-5
- [31] Kirmizigil B, Chauchat JR, Yalciner O, et al. The Effectiveness of Kinesio Taping in
- 597Recovering From Delayed Onset Muscle Soreness: A Crossover Study. J Sport Rehabil
- 598 2019;29:385-93. doi:10.1123/jsr.2018-0389
- [32] Liu K, Duan Z, Chen L, et al. Short-Term Effect of Different Taping Methods on Local
- 600 Skin Temperature in Healthy Adults. *Front Physiol* 2020;11:488.
- 601 doi:10.3389/fphys.2020.00488
- [33] Lam J, Chan P, Constantinou M, et al. Personal belief on elastic tape and tape tension
- affect perceived performance, but not muscle activity and endurance. *Physiother Theory*
- 604 *Pract* 2023;39:1-7. doi:10.1080/09593985.2023.2172703
- [34] Au IPH, Fan PCP, Lee WY, et al. Effects of Kinesio tape in individuals with lateral
- 606 epicondylitis: A deceptive crossover trial. *Physiother Theory Pract* 2017;33:914-9.
- 607 doi:10.1080/09593985.2017.1359871
- 608 [35] Mak DN, Au IP, Chan M, et al. Placebo effect of facilitatory Kinesio tape on muscle
- activity and muscle strength. *Physiother Theory Pract* 2019;35:157-62.

## 610 doi:10.1080/09593985.2018.1441936

- 611 [36] Chinese expert consensus group of clinical application of kinesio taping. Clinical
- 612 application of kinesio taping in China: Expert consensus. *Chinese Journal of Physical*
- 613 *Medicine and Rehabilitation* 2021;43:97-108. doi:10.3760/cma.j.issn.0254-
- 614 1424.2021.02.001
- [37] Ramírez-Vélez R, Hormazábal-Aguayo I, Izquierdo M, et al. Effects of kinesio taping
- alone versus sham taping in individuals with musculoskeletal conditions after
- 617 intervention for at least one week: a systematic review and meta-analysis. *Physiotherapy*
- 618 2019;105:412-20. doi:10.1016/j.physio.2019.04.001
- [38] Parreira Pdo C, Costa Lda C, Hespanhol LC Jr, et al. Current evidence does not support
- 620 the use of Kinesio Taping in clinical practice: a systematic review. *J Physiother*
- 621 2014;60:31-9. doi:10.1016/j.jphys.2013.12.008
- [39] Kalron A, Bar-Sela S. A systematic review of the effectiveness of Kinesio Taping--fact or
- 623 fashion?. *Eur J Phys Rehabil Med* 2013;49:699-709.
- [40] Morris D, Jones D, Ryan H, et al. The clinical effects of Kinesio® Tex taping: A

625 systematic review. *Physiother Theory Pract* 2013;29:259-70.

- 626 doi:10.3109/09593985.2012.731675
- 627 [41] Landesa-Piñeiro L, Leirós-Rodríguez R. Physiotherapy treatment of lateral epicondylitis:
- 628 A systematic review. J Back Musculoskelet Rehabil 2022;35:463-77. doi:10.3233/BMR-

629 210053

- 630 [42] George CE, Heales LJ, Stanton R, et al. Sticking to the facts: A systematic review of the
- 631 effects of therapeutic tape in lateral epicondylalgia. *Phys Ther Sport* 2019;40:117-27.

## 632 doi:10.1016/j.ptsp.2019.08.011

633	[43]	Gianola S	, Iannicelli V	/, I	Fascio E.	, et al.	Kinesio	taping	for rotator	cuff d	lisease.	Cochrane
-----	------	-----------	----------------	------	-----------	----------	---------	--------	-------------	--------	----------	----------

- 634 Database Syst Rev 2021;8:CD012720. doi:10.1002/14651858.CD012720.pub2
- [44] Ghozy S, Dung NM, Morra ME, et al. Efficacy of kinesio taping in treatment of shoulder
- pain and disability: a systematic review and meta-analysis of randomised controlled

637 trials. *Physiotherapy* 2020;107:176-88. doi:10.1016/j.physio.2019.12.001

- 638 [45] Celik D, Karaborklu Argut S, Coban O, et al. The clinical efficacy of kinesio taping in
- 639 shoulder disorders: a systematic review and meta analysis. *Clin Rehabil* 2020;34:723-40.
- 640 doi:10.1177/0269215520917747
- [46] Pan L, Li Y, Gao L, et al. Effects of Kinesio Taping for Chronic Nonspecific Low Back
- Pain: A Systematic Review and Meta-analysis. *Altern Ther Health Med* 2023;29:68-76.
- [47] Sheng Y, Duan Z, Qu Q, et al. Kinesio taping in treatment of chronic non-specific low
- back pain: a systematic review and meta-analysis. *J Rehabil Med* 2019;51:734-40.
- 645 doi:10.2340/16501977-2605
- [48] Luz Júnior MAD, Almeida MO, Santos RS, et al. Effectiveness of Kinesio Taping in
- 647 Patients With Chronic Nonspecific Low Back Pain: A Systematic Review With Meta-

648 analysis. *Spine* 2019;44:68-78. doi:10.1097/BRS.00000000002756

- [49] Melese H, Alamer A, Hailu Temesgen M, et al. Effectiveness of Kinesio Taping on the
- 650 Management of Knee Osteoarthritis: A Systematic Review of Randomized Controlled
- 651 Trials. J Pain Res 2020;13:1267-76. doi:10.2147/JPR.S249567
- [50] Wu H, Yao R, Wu J, et al. Does kinesio taping plus exercise improve pain and function in
- patients with knee osteoarthritis?: A systematic review and meta-analysis of randomized

654	controlled trials. Front Physiol 2022;13:961264. doi:10.3389/fphys.2022.961264
655	[51] Ouyang JH, Chang KH, Hsu WY, et al. Non-elastic taping, but not elastic taping,
656	provides benefits for patients with knee osteoarthritis: systemic review and meta-
657	analysis. Clin Rehabil 2018;32:3-17. doi:10.1177/0269215517717307
658	[52] Vanti C, Bertozzi L, Gardenghi I, et al. Effect of taping on spinal pain and disability:
659	systematic review and meta-analysis of randomized trials. Phys Ther 2015;95:493-506.
660	doi:10.2522/ptj.20130619
661	[53] McGlothlin AE, Lewis RJ. Minimal clinically important difference: defining what really
662	matters to patients. JAMA 2014;312:1342-3. doi:10.1001/jama.2014.13128
663	[54] Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the
664	minimal clinically important difference. Control Clin Trials 1989;10:407-15.
665	doi:10.1016/0197-2456(89)90005-6
666	[55] Sedaghat AR. Understanding the Minimal Clinically Important Difference (MCID) of
667	Patient-Reported Outcome Measures. Otolaryngol Head Neck Surg 2019;161:551-60.
668	doi:10.1177/0194599819852604
669	[56] Engel L, Beaton DE, Touma Z. Minimal Clinically Important Difference: A Review of
670	Outcome Measure Score Interpretation. Rheum Dis Clin North Am 2018;44:177-88.
671	doi:10.1016/j.rdc.2018.01.011
672	[57] Angst F, Aeschlimann A, Angst J. The minimal clinically important difference raised the
673	significance of outcome effects above the statistical level, with methodological
674	implications for future studies. J Clin Epidemiol 2017;82:128-36.
675	doi:10.1016/j.jclinepi.2016.11.016

- 676 [58] Embry TW, Piccirillo JF. Minimal Clinically Important Difference Reporting in
- 677 Randomized Clinical Trials. *JAMA Otolaryngol Head Neck Surg* 2020;146:862-3.
- 678 doi:10.1001/jamaoto.2020.1586
- [59] Cheatham SW, Baker RT, Abdenour TE. Kinesiology Tape: A Descriptive Survey of
- 680 Healthcare Professionals in the United States. *Int J Sports Phys Ther* 2021;16:778-96.
- 681 doi:10.26603/001c.22136
- [60] Hill CE, Stanton R, Heales LJ, et al. Therapeutic tape use for lateral elbow tendinopathy:
- 683 A survey of Australian healthcare practitioners. *Musculoskelet Sci Pract* 2020;48:102160.
- 684 doi:10.1016/j.msksp.2020.102160
- [61] Hunt H, Pollock A, Campbell P, et al. An introduction to overviews of reviews: planning
- a relevant research question and objective for an overview. *Syst Rev* 2018;7:39.
- 687 doi:10.1186/s13643-018-0695-8
- [62] Lunny C, Brennan SE, McDonald S, et al. Toward a comprehensive evidence map of
- 689 overview of systematic review methods: paper 1-purpose, eligibility, search and data
- 690 extraction. *Syst Rev* 2017;6:231. doi:10.1186/s13643-017-0617-1
- [63] Alahdab F, Murad MH. Evidence maps: a tool to guide research agenda setting. *BMJ*

692 Evid Based Med 2019;24:209-11. doi:10.1136/bmjebm-2018-111137

- [64] Miake-Lye IM, Hempel S, Shanman R, et al. What is an evidence map? A systematic
- 694 review of published evidence maps and their definitions, methods, and products. *Syst Rev*
- 695 2016;5:28. doi:10.1186/s13643-016-0204-x
- [65] Cupler ZA, Alrwaily M, Polakowski E, et al. Taping for conditions of the
- 697 musculoskeletal system: an evidence map review. *Chiropr Man Therap* 2020;28:52.

- 698 doi:10.1186/s12998-020-00337-2
- [66] Saran A, White H. Evidence and gap maps: a comparison of different
- 700 approaches. *Campbell Syst Rev* 2018;14:1-38. doi:10.4073/cmdp.2018.2
- [67] Lu L, Zhang Y, Ge S, et al. Evidence mapping and overview of systematic reviews of the
- effects of acupuncture therapies. *BMJ Open* 2022;12:e056803. doi:10.1136/bmjopen-
- 703 2021-056803
- [68] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review
- and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- 706 doi:10.1186/2046-4053-4-1
- 707 [69] Pollock M, Fernandes RM, Becker LA, et al. Chapter V: Overviews of Reviews. In:
- 708 Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic
- 709 Reviews of Interventions version 6.4. Cochrane, 2023. Available:
- 710 www.training.cochrane.org/handbook.
- [70] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated
- guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi:10.1136/bmj.n71
- [71] World Health Organization. ICD-11 for Mortality and Morbidity Statistics [online]. 2024.
- 714 https://icd.who.int/browse11/l-m/en (accessed 26 January 2024).
- [72] Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials
- 716 2017;18:280. doi:10.1186/s13063-017-1978-4
- [73] Kirkham JJ, Davis K, Altman DG, et al. Core Outcome Set-STAndards for Development:
- The COS-STAD recommendations. *PLoS Med* 2017;14:e1002447.
- 719 doi:10.1371/journal.pmed.1002447

- 720 [74] Black N. Patient reported outcome measures could help transform healthcare. BMJ
- 2013;346:f167. doi:10.1136/bmj.f167 721
- [75] Møller MH. Patient-important outcomes and core outcome sets: increased attention 722
- 723 needed!. Br J Anaesth 2019;122:408-10. doi:10.1016/j.bja.2019.02.007
- [76] Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the 724
- PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev 725
- 726 2021;10:39. doi:10.1186/s13643-020-01542-z
- [77] Gwet KL. Handbook of Inter-Rater Reliability: The Definitive Guide to Measuring the 727
- Extent of Agreement Among Raters: 4th ed. Gaithersburg: Advances Analytics 2014:101-728 28.
- 729
- 730 [78] Vach W, Gerke O. Gwet's AC1 is not a substitute for Cohen's kappa - A comparison of
- basic properties. *MethodsX* 2023;10:102212. doi:10.1016/j.mex.2023.102212 731
- [79] Page MJ, Sterne JAC, Boutron I, et al. ROB-ME: a tool for assessing risk of bias due to 732
- missing evidence in systematic reviews with meta-analysis. BMJ 2023;383:e076754. 733
- doi:10.1136/bmj-2023-076754 734
- [80] Lunny C, Pieper D, Thabet P, et al. Managing overlap of primary study results across 735
- systematic reviews: practical considerations for authors of overviews of reviews. BMC 736
- Med Res Methodol 2021;21:140. doi:10.1186/s12874-021-01269-y 737
- [81] Pérez-Bracchiglione J, Meza N, Bangdiwala SI, et al. Graphical Representation of 738
- Overlap for OVErviews: GROOVE tool. Res Synth Methods 2022;13:381-8. 739
- doi:10.1002/jrsm.1557 740
- [82] Pieper D, Antoine SL, Mathes T, et al. Systematic review finds overlapping reviews were 741

- not mentioned in every other overview. *J Clin Epidemiol* 2014;67:368-75.
- 743 doi:10.1016/j.jclinepi.2013.11.007
- [83] Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in
- systematic reviews: reporting guideline. *BMJ* 2020;368:16890. doi:10.1136/bmj.16890
- [84] Perry R, Whitmarsh A, Leach V, et al. A comparison of two assessment tools used in
- 747 overviews of systematic reviews: ROBIS versus AMSTAR-2. *Syst Rev* 2021;10:273.
- 748 doi:10.1186/s13643-021-01819-x
- [85] Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic
- reviews that include randomised or non-randomised studies of healthcare interventions,
- 751 or both. *BMJ* 2017;358:j4008. doi:10.1136/bmj.j4008
- 752 [86] Whiting P, Savović J, Higgins JP, et al. ROBIS: A new tool to assess risk of bias in
- 753 systematic reviews was developed. *J Clin Epidemiol* 2016;69:225-34.
- 754 doi:10.1016/j.jclinepi.2015.06.005
- [87] Lorenz RC, Matthias K, Pieper D, et al. A psychometric study found AMSTAR 2 to be a
- valid and moderately reliable appraisal tool. *J Clin Epidemiol* 2019;114:133-40.
- 757 doi:10.1016/j.jclinepi.2019.05.028
- [88] Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in
- 759 randomised trials. *BMJ* 2019;366:14898. doi:10.1136/bmj.14898
- 760 [89] Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals,
- and power: a guide to misinterpretations. *Eur J Epidemiol* 2016;31:337-50.
- 762 doi:10.1007/s10654-016-0149-3
- 763 [90] McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings using other

764	methods. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for
-----	---

- 765 Systematic Reviews of Interventions version 6.4. Cochrane, 2023. Available:
- 766 www.training.cochrane.org/handbook.
- 767 [91] Balasubramanian H, Ananthan A, Rao S, et al. Odds ratio vs risk ratio in randomized
- 768 controlled trials. *Postgrad Med* 2015;127:359-67. doi:10.1080/00325481.2015.1022494
- [92] Knol MJ, Duijnhoven RG, Grobbee DE, et al. Potential misinterpretation of treatment
- effects due to use of odds ratios and logistic regression in randomized controlled
- trials. *PLoS One* 2011;6:e21248. doi:10.1371/journal.pone.0021248
- [93] Andrade C. Mean Difference, Standardized Mean Difference (SMD), and Their Use in
- 773 Meta-Analysis: As Simple as It Gets. *J Clin Psychiatry* 2020;81:20f13681.
- 774 doi:10.4088/JCP.20f13681
- [94] Belur J, Tompson L, Thornton A, et al. Interrater Reliability in Systematic Review
- 776 Methodology: Exploring Variation in Coder Decision-Making. Sociological Methods &
- 777 *Research* 2021;50:837-65. doi:10.1177/0049124118799372
- [95] Moja L, Fernandez del Rio MP, Banzi R, et al. Multiple systematic reviews: methods for
- assessing discordances of results. *Intern Emerg Med* 2012;7:563-8. doi:10.1007/s11739-

780 012-0846-1

- [96] Lunny C, Brennan SE, McDonald S, et al. Toward a comprehensive evidence map of
- 782 overview of systematic review methods: paper 2-risk of bias assessment; synthesis,
- 783 presentation and summary of the findings; and assessment of the certainty of the
- 784 evidence. *Syst Rev* 2018;7:159. doi:10.1186/s13643-018-0784-8
- [97] Lunny C, Thirugnanasampanthar SS, Kanji S, et al. How can clinicians choose between

786	conflicting and discordant systematic reviews? A replication study of the Jadad
787	algorithm. BMC Med Res Methodol 2022;22:276. doi:10.1186/s12874-022-01750-2
788	[98] Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of
789	articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011;64:380-2.
790	doi:10.1016/j.jclinepi.2010.09.011
791	[99] Schünemann HJ, Higgins JPT, Vist GE, et al. Chapter 14: Completing 'Summary of
792	findings' tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J,
793	Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions
794	version 6.4. Cochrane, 2023. Available: www.training.cochrane.org/handbook.
795	[100]Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating
796	quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
797	doi:10.1136/bmj.39489.470347.AD
798	[101]Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality
799	of evidence. J Clin Epidemiol 2011;64:401-6. doi:10.1016/j.jclinepi.2010.07.015
800	[102]Katajapuu N, Heinonen A, Saltychev M. Minimal clinically important difference and
801	minimal detectable change of the World Health Organization Disability Assessment
802	Schedule 2.0 (WHODAS 2.0) amongst patients with chronic musculoskeletal pain. Clin
803	Rehabil 2020;34:1506-11. doi:10.1177/0269215520942573
804	[103]Benaim C, Blaser S, Léger B, et al. "Minimal clinically important difference" estimates
805	of 6 commonly-used performance tests in patients with chronic musculoskeletal pain
806	completing a work-related multidisciplinary rehabilitation program. BMC Musculoskelet
807	Disord 2019;20:16. doi:10.1186/s12891-018-2382-2

- 808 [104]Franchignoni F, Vercelli S, Giordano A, et al. Minimal clinically important difference of
- the disabilities of the arm, shoulder and hand outcome measure (DASH) and its shortened
- 810 version (QuickDASH). J Orthop Sports Phys Ther 2014;44:30-9.
- 811 doi:10.2519/jospt.2014.4893
- 812 [105]Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic
- 813 musculoskeletal pain intensity measured on a numerical rating scale. *Eur J Pain*
- 814 2004;8:283-91. doi:10.1016/j.ejpain.2003.09.004
- [106] Vickers AJ. The use of percentage change from baseline as an outcome in a controlled
- trial is statistically inefficient: a simulation study. *BMC Med Res Methodol* 2001;1:6.
- 817 doi:10.1186/1471-2288-1-6
- 818 [107]Man-Son-Hing M, Laupacis A, O'Rourke K, et al. Determination of the clinical
- 819 importance of study results. *J Gen Intern Med* 2002;17:469-76. doi:10.1046/j.1525-
- 820 1497.2002.11111.x
- [108] Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. *Evid Based*
- 822 *Ment Health* 2018;21:95-100. doi:10.1136/ebmental-2018-300014
- 823 [109]Huang Y, Chen Z, Chen B, et al. Dietary sugar consumption and health: umbrella

review. *BMJ* 2023;381:e071609. doi:10.1136/bmj-2022-071609

- [110]Berendsen S, Berendse S, van der Torren J, et al. Cognitive behavioural therapy for the
- treatment of schizophrenia spectrum disorders: an umbrella review of meta-analyses of
- randomised controlled trials. *EclinicalMedicine* 2024;67:102392.
- doi:10.1016/j.eclinm.2023.102392
- 829 [111] Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant

- findings. *Clin Trials* 2007;4:245-53. doi:10.1177/1740774507079441
- [112]Gates M, Gates A, Pieper D, et al. Reporting guideline for overviews of reviews of
- healthcare interventions: development of the PRIOR statement. *BMJ* 2022;378:e070849.
- 833 doi:10.1136/bmj-2022-070849

834

# 835 **FIGURE LEGENDS**

- Figure 1 Method of interpreting clinical relevance developed by Man-Son-Hing et al.[107] and
- 837 adapted. Dotted lines represent the clinical relevance threshold. MCID, minimal clinically
- 838 important difference.



839